Analyzing Biosig Technologies (NASDAQ:STEX) & Ellington Credit (NYSE:EARN)

Ellington Credit (NYSE:EARN) and Biosig Technologies (NASDAQ:STEX) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ellington Credit and Biosig Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ellington Credit	0	1	1	0	2.50
Biosig Technologies	1	0	1	0	2.00

Ellington Credit presently has a consensus target price of $5.50, suggesting a potential upside of 27.17%. Biosig Technologies has a consensus target price of $4.00, suggesting a potential upside of 504.87%. Given Biosig Technologies’ higher possible upside, analysts plainly believe Biosig Technologies is more favorable than Ellington Credit.

Volatility and Risk

Ellington Credit has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ellington Credit and Biosig Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ellington Credit	$51.80 million	3.19	-$38.85 million	($0.98)	-4.41
Biosig Technologies	$40,000.00	1,925.37	-$462.77 million	($9.05)	-0.07

Ellington Credit has higher revenue and earnings than Biosig Technologies. Ellington Credit is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ellington Credit and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ellington Credit	-70.52%	N/A	N/A
Biosig Technologies	N/A	-462.48%	-307.38%

Institutional and Insider Ownership

20.4% of Ellington Credit shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 1.4% of Ellington Credit shares are held by company insiders. Comparatively, 52.7% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ellington Credit beats Biosig Technologies on 7 of the 13 factors compared between the two stocks.

About Ellington Credit

Ellington Credit Company, a real estate investment trust, acquires, invests in, and manages residential mortgage-and real estate-related assets. It acquires and manages residential mortgage-backed securities (RMBS), including agency pools and agency collateralized mortgage obligations (CMOs); and non-agency RMBS, such as non-agency CMOs, such as investment grade and non-investment grade. The company has elected to be taxed as a real estate investment trust. As a result, it would not be subject to corporate income tax on that portion of its net income that is distributed to shareholders. The company was formerly known as Ellington Residential Mortgage REIT and changed its name to Ellington Credit Company in April 2024. Ellington Credit Company was incorporated in 2012 and is based in Old Greenwich, Connecticut.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.